OrkinC, OkaS, PhilibertP, et al.Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV, 2021; 8(4):e185–e196; doi: 10.1016/S2352-3018(20)30340-4
2.
MorenoC, IzquierdoR, AlejosB, et al.; CoRIS Cohort. Acceptability of long-acting injectable antiretroviral treatment for HIV management: Perspectives of patients and physicians in Spain. AIDS Patient Care STDS, 2024; 38(7):305–314; doi: 10.1089/apc.2024.0093
3.
BartalucciC, BaldiF, RicciE, et al.People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: Who are they? AIDS, 2024; 38(3):430–434; doi: 10.1097/QAD.0000000000003766
4.
MazzitelliM, AvolioA, CarandinaR, et al.Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine. J Antimicrob Chemother, 2024; 79(8):2074–2076; doi: 10.1093/jac/dkae187
5.
AdachiE, OwadaR, SatoS, et al.Febrile gluteal inflammation evident on imaging findings after long-acting cabotegravir administration. Clin Infect Dis, 2024; 78(6):1769–1770; doi: 10.1093/cid/ciad705
6.
TeichnerP, ChamayN, ElliotE, et al.Cabotegravir + rilpivirine long-acting: Overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration. Open Forum Infect Dis, 2024; 11(6):ofae282; doi: 10.1093/ofid/ofae282
7.
JuckerBM, FuchsEJ, LeeS, et al.Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers. Br J Clin Pharmacol, 2022; 88(4):1655–1666; doi: 10.1111/bcp.14977
8.
AyindeO, HaywardRS, RossJDC. The effect of intramuscular injection technique on injection associated pain; a systematic review and meta-analysis. PLoS One, 2021; 16(5):e0250883; doi: 10.1371/journal.pone.0250883
9.
TaramassoL, BonoraS, CingolaniA, et al.Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV. J Antimicrob Chemother, 2025; 80(3):610–623; doi: 10.1093/jac/dkaf025
10.
D’AmicoR, HanK, MinS, et al.Subcutaneous injections of cabotegravir + rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS, 2025; 39:(15):2182–2190; doi: 10.1097/QAD.0000000000004310
11.
LandovitzRJ, HanscomBS, ClementME, et al.; HPTN 083 Study Team. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV, 2023; 10(12):e767–e778; doi: 10.1016/S2352-3018(23)00261-8
